mRNA cancer vaccine study for advanced solid tumors
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests two new mRNA-based vaccines, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. It aims to see if the vaccines are safe and can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of cancer listed for the group you're in (like melanoma, lung, liver, or colorectal cancer) that has spread or cannot be removed.
- Your cancer must have gotten worse after or not responded to standard treatments.
- You need to be able to have a small sample of your tumor taken (biopsy) for testing, or have an older tissue sample.
- You should be well enough to perform basic daily tasks (ECOG score of 0 or 1).
- You must have acceptable blood and organ function.
- If you can become pregnant, you must have a negative pregnancy test before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests an mRNA vaccine (mRNA-4359) either alone or combined with an immune checkpoint antibody (immunotherapy). It’s for people with advanced solid tumors to see if it can shrink tumors and how safe it is.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
This Phase 1/2 study tests a new cancer drug (S-531011) in people with advanced or metastatic solid tumors, either by itself or combined with an immunotherapy drug. It may help shrink tumors and learn how the treatment works, but it also requires extra procedures like repeat tumor biopsies and frequent monitoring.
This trial tests whether a personalized mRNA vaccine, given with pembrolizumab, can help people with advanced solid tumors by training the immune system to recognize cancer. It is mainly for patients whose tumor tissue matches specific genetic and immune patterns, and who meet key safety and infection requirements.
This early-stage trial tests a new mRNA-based drug designed to help your immune system fight advanced cancers that haven't responded to standard treatments. The study measures safety, tolerability, and whether it can slow or shrink your tumor.
This trial tests a new mRNA vaccine that targets a unique part of your tumor cells, given together with an immunotherapy drug (anti-PD-1). It is for people with advanced solid tumors that have not responded to standard treatments.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.